Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2026-04-27 @ 9:45 AM
Study NCT ID:
NCT05841134
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-05-09
First Post:
2023-04-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
T-CAPOX-MSI-H-CRC-
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None